Introduction
============

According to the WHO, cancer is still the second leading cause of death worldwide, and was responsible for 8.8 million deaths in 2015. Globally, an almost one-in-six death is due to cancer [@B1]. Cancer is a generic terminology for a large group of diseases which can influence any part of the body. Recurrence and metastasis are the major causes of death and poor outcome for cancer. Therefore, it is pivotal for us to identify better predictors for prognosis in patients with cancer.

It is well known that inflammation can increase tumor risk and influence all tumor stages, triggering the initial genetic mutation or epigenetic mechanism, promoting tumor initiation, metastasis and progression [@B2]. Thus, inflammation parameter is a powerful candidate to predict cancer outcome. In recent years, many inflammatory markers, such as C-reaction protein (CRP), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and monocyte-to-lymphocyte ratio (MLR) have been studied in association with poor prognosis of cancers [@B3]-[@B6].

Systemic immune-inflammation index (SII),a new inflammatory index, based on neutrophil, platelet and lymphocyte counts has been recently suggested to be associated with poor outcome in Hepatocellular carcinoma [@B7], Esophageal squamous cell carcinoma[@B8],Small Cell Lung Cancer[@B9],and so on. However, due to the different of the study design or sample size, there are still some contrary views [@B10], [@B11]. The association between SII and cancer prognosis is controversial.

Therefore, it is necessary for us to estimate the prognostic value of SII in patients with cancer. Thus, in this study, we performed a meta-analysis to investigate the prognostic role of SII in patients with various cancers.

Materials and Methods
=====================

Search strategy
---------------

The Pubmed, Embase, PMC, Web of Science and Cochrane Library databases were searched up to February 15, 2018 with the search strategy ( SII OR "Systemic immune-inflammation index") AND (cancer OR tumor OR carcinomas OR neoplasm) AND (prognosis OR outcome OR mortality OR survival OR recurrence OR metastasis OR progression) by two independently authors (RN Yang and Q Chang). The language was limited to English.

Inclusion and exclusion criteria
--------------------------------

Inclusion criteria were as follow: (1) the roles of SII in cancer patients were investigated. (2) Pretreatment SII and cutoff values were reported. (3) SII was used as prognostic indicators of OS, CSS or PFS or TTR or DFS or RFS. (4) Sufficient data for the computation of hazard ratios (HR) and corresponding 95% confidence intervals (CI) were reported.

The exclusion criteria are the following: (1) duplicate publications. (2) Review, conference abstract, letter, not full text in English. (3) Studies with insufficient data. (4) Animals studies.

Data extraction and quality assessment
--------------------------------------

Two authors independently evaluated the survival data and study characteristics from the selected articles that met the inclusion criteria. Disagreements were resolved by third individual.

The quality of studies was evaluated by Newcastle-Ottawa quality assessment Scale (NOS) [@B39], which includes 3 parts: assessment of selection of the exposed and unexposed cohort (0-4 points), comparability of the two cohorts (0-2 points), and outcome assessment (0-3 points) and they were summarized in supplement material (**Table [S1](#SM0){ref-type="supplementary-material"}**). The scores ranged from 0 to 9 points, with≥6 points denoting high quality.

Statistical analysis
--------------------

Pooled HRs and 95% CIs were extracted from each study to assess prognostic role of SII in cancer patients. Heterogeneity among studies was tested by Cochran\'s *Q* test and the Higgins\'*I*[@B2] statistic. If the*I[@B2]*≥50% and*P*\<0.05, random-effects models was used to generate the pooled HRs, if not, fixed-effects were performed. Egger\'s test and Begg\'s test were applied to evaluate publication bias. Sensitivity analysis was performed to evaluate the stability of the results. All statistical analyses were conducted with STATA version 12.0 (StataCorp, College Station, TX, USA).

Results
=======

Search results and characteristics of the included study
--------------------------------------------------------

As is shown in the **Figure [1](#F1){ref-type="fig"},** initially 198 records were identified through the electronic database. After removed duplicates and excluded by title and/or abstract, 28 articles were selected. In these 28 articles, 5 articles were conference abstract without full text, and another was irrelevant records. Therefore, there were 22 articles involving 7657 patients enrolled. In these included articles, 20 articles conducted retrospective analysis, one of them performed Propensity Score-matched retrospective Analysis, one article conducted prospective analysis and the last one had both a retrospective design and a prospectively design in two independent patients population. Therefore, a total of 22 articles including 24 studies were included in this analysis.

As is listed in **Table [1](#T1){ref-type="table"}**, all articles were published between 2014 and 2017 in English peer-reviewed journals. Among these articles, 16 articles [@B7]-[@B12], [@B14], [@B17], [@B20]-[@B25], [@B27], [@B28] were from China, 4 articles [@B13],[@B15],[@B16],[@B19] were from Italy, one was from Korea[@B18] and another was from France[@B26]. These articles included a variety of cancers, among them 6 for Hepatocellular carcinoma, 3 for Esophageal squamous cell carcinoma (ESCC), 3 for Gastric Cancer, 3 for colorectal cancer, one for Small Cell Lung Cancer (SCLC), one for Prostate cancer, one for Renal cell cancer, one for Biliary tract cancer, one for Malignant obstructive jaundice, one for non-small cell lung cancer (NSCLC) and one for Acral Melanoma.. As shown in Table [1](#T1){ref-type="table"}, the reference of 7 and 8 were performed in two independent patient populations, they separately had two HRs. Thus we expressed them in this way that "one article but two studies". Therefore, a total of 22 articles but 24 studies enrolling 7657 patients were included in this manuscript. Among them, 20 articles but 22 studies involving 7196 patients reported OS, 3 articles but 4 studies including 602 patients reported TTR, 5 articles comprising 1205 patients reported PFS and respectively, 298, 280 and 226 patients reported CSS, DFS and RFS. The cutoff value of SII in these articles was not uniform and ranged from 300 to1600, sample size varied from 33 to 919 with a medium sample size of 560. As for the quality evaluation of selected studies, the NOS of nine included articles was 9, nine included articles was 8 and four was 7.

Meta-analysis results
---------------------

### Overall survival

A total of 7196 patients were included in the analysis of HR for OS. As shown in **Figure [2](#F2){ref-type="fig"}.** The combined result revealed that in comparison with a low SII , a high SII was evidently correlated with poor OS (HR=1.69, 95%CI=1.42-2.01, *p*\<0.001), and because of obvious heterogeneity (*I[@B2]* = 78.5%, *Ph* = 0.000), a random-effect model was applied. Subgroup analysis was conducted to evaluate HR of OS by ethnicity, cancer type, sample size, cutoff value (**Table [2](#T2){ref-type="table"}**). In the subgroup analysis by cancer type, high SII predicted poor OS in Hepatocellular carcinoma (HR=2.11, 95%CI=1.59-2.80,*p*\<0.001), Gastric Cancer (HR=1.43, 95%CI=1.12-1.83,*p*=0.005), ESCC (HR=1.5, 95%=1.09-2.06,*p*=0.013), Urinary tract cancer (HR=1.82, 95%CI=1.44-2.32,*p*\<0.001), and other cancers include SCLC, Acral Melanoma and NSCLC (HR=1.77, 95%CI=1.30-2.41,*p*\<0.001) and good effect size was observed in the hepatocellular carcinoma (HR=2.11) . Overall prognostic ability of SII was low in g Gastric Cancer and ESCC (HR= 1.43, 1.5 respectively). High SII had a negative impact on overall survival in Asian (*p \<* 0.001) and Caucasian (*p =*0009) populations. Pooled HR results were also \>1 in the subgroups of sample size and cutoff value, the differences between them were statistically significant (*p*\<0.001).

In addition, meta-regression was used to investigate the influence of different subgroups of SII on the prognosis of cancer and according to the results they did not significantly impact our merge HR. (*p~studydesign=~*0.157*, p* ~c*ancer\ type*~=0.412, *p~Ethnicity~*=0.777,*p* ~cutoff~ =0.139, *p ~sample\ size~ =*0.513,*p* ~country~= 0.572, *p~nos~*=0.528,*p~model~*=0.504).

### Publication bias

Begg\'s funnel plot and Egger\'s test were used to assess potential publication bias in this meta-analysis. The *p* values for OS were 0.114 (Begg\'s test) and 0.741 (Egger\'s test) and there was no publication bias. (**Figure [3](#F3){ref-type="fig"}**)

### Sensitivity analyses

We performed leave-one-out sensitivity analysis to check if any study influenced the HR of OS. According to the senstivity analysis result, getting rid of any single literature did not significantly alter the pooled HR indicating that our analysis result was robustness. (**Figure [4](#F4){ref-type="fig"}**)

#### Time to recurrent

A total of three articles consisted of 602 patients reported HR for TTR. The heterogeneity test showed no obvious heterogeneity and a fixed-effect model was used (*I[@B2]*=0.0%, *p~h~* =0.664).The pooled HR was 1.87 (95%CI=1.42-2.47, *p*\<0.001) revealing the significant relationship between high SII level and poor TTR in cancers. (**Figure [5](#F5){ref-type="fig"}**)

### Progress-free survival

Five articles comprising 1205 patients reported HR for PFS. The random-effect model was performed (*I[@B2]*=89.8%, *p~h~*=0.000). The combined result revealed that SII over the cutoff was related to the worse PFS outcome (HR=1.61, 95%CI=1.11-2.35, *p=*0.012). (**Figure [5](#F5){ref-type="fig"}**)

Because of high heterogeneity, sensitivity analysis was used to check the robustness of the result. As shown in **Figure [6](#F6){ref-type="fig"},** any single study did not substantially influence the merged HRs when deleted from the whole study.

### Cancer-specific survival, Disease-free survival and Relapse-free survival

There were three articles separately reported HR for CSS, DFS and RFS. The merged HR was 1.44 (*p*=0.027), 2.70 (*p*\<0.001) and 1.66 (*p*=0.025) respectively, indicating significant association between high SII and poor CSS DFS, and RFS in cancers. (**Figure [5](#F5){ref-type="fig"}**)

Discussion
==========

The relationship between SII and prognosis in cancer patients is still contentious. Therefore, we performed a meta-analysis including 22 articles and a total of 7657 patients to investigate the prognostic value of SII in cancer patients. Before this study, there was an article showed that high SII indicated a worse overall survival in all gastrointestinal tract cancers and was not associated with a hazard ratio for worse PFS outcome [@B29]. However, in our meta-analysis, we come to a different conclusion. According to the result, High SII was associated with worse outcome of OS, TTR, PFS, CSS, DFS and RFS (HR=1.69, 1.87, 1.61, 1.44, 2.70 and 1.66 respectively). Subgroup analysis also indicated that SII over the cutoff value could predict worse OS in Hepatocellular carcinoma (*p*\<0.001), Gastric cancer (*p*=0.005), Esophageal Squamous Cell Carcinoma (*p*=0.013), Urinary system cancer (*p*\<0.001), Small cell lung cancer (*p*\<0.001), Non-Small cell lung cancer (*p*\<0.001) and Acral Melanoma (*p*\<0.001), not colorectal cancer (*p*=0.313). The cutoff value of SII in these articles was not uniform, but the result of meta-regression analysis has shown that it did not influence our results. Nevertheless, we still need to adjust the optimal cutoff according to the clinical parameters in future clinical trials.

Inflammatory responses have been confirmed to play decisive roles at different stages of cancer development, including initiation, malignant conversion, promotion, tissue infiltration and metastasis [@B30]. SII , a new inflammatory index, based on neutrophil, lymphocyte and platelet counts has been recently suggested to be associated with poor outcome of cancer, and it was also reported to have a significant correlation with the number of circulating tumor cells which greatly promote the metastatic of cancer[@B31].

Several possible mechanisms can make explanation for the prognostic values of SII in cancer. Cancer patients often suffer from thromboembolic diseases[@B17]. And the causes of thrombocytosis may be that some tumor cells can produce and increase thrombopoietin (TPO), in addition, several platelet activation markers, such as P-selectin, β-thromboglobulin or CD40 ligand have been found to be up-regulated and contribute to the increase of platelet [@B32]. Platelet-derived TGF-β not only down-regulates the cytokine NKG2D (Natural Killer Group 2, member D) on NK-cell surface to protect tumor cells from immune system surveillance but activates TGF-β/Smad to promote epithelial-mesenchymal transition (EMT) which contributes to the metastasis of cancer, and the direct interaction between cancer cells and platelets activates the NF-κb signaling, which in coordination with TGF-β signaling facilitates EMT and metastasis. Platelets are also able to mediate tumor cell survival and growth at distant sites by governing formation of metastatic niches [@B33]-[@B35]. Recent years, lots of evidence have shown that neutrophils can promote tumor metastasis, neutrophil numbers, neutrophil-related factors, such as nitric oxide, arginase, IL-6 and functions have been associated with the progress of cancer[@B27].In addition, platelets have been recognized to recruit and activate granulocytic cells in the tumor tissues, indicating that the platelet may be also essential for generation of tumor-associated neutrophils [@B36]. Lymphocytes play significant roles in the balance between body defense and noxious agents involved in a number of diseases, including cancer. They induce cytotoxic cell death and inhibit tumor cell proliferation and migration, improve prognosis of cancer [@B37]-[@B38].

However, there are still some limitations in our meta-analysis. Firstly, the types of the cancers and their number were limited. Secondly, the studies included in our analysis mostly were retrospective studies and were published in English, which was more susceptible to potential biases. Thirdly, the cutoff value of SII was different in our analysis. Finally, there were some studies which did not focus on SII may be the sources of heterogeneity.

In summary, our meta-analysis reveals that high SII may be a reliable prognostic factor for worse OS of various cancers. However, given the limited number of studies included in the analysis, large-scale prospective and well-designed studies are also needed to be performed to confirm the conclusion in the future.
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###### 

The characteristics of included studies

  Study            Year   Country   Ethnicity   Cancer type                  Sample size   Cutoff value   Outcome   NOS   Analysis
  ---------------- ------ --------- ----------- ---------------------------- ------------- -------------- --------- ----- ----------
  Hu\[7\]          2014   China     Asian       Hepatocellular carcinoma     123 and133    330            OS, TTR   8     M
  Liu\[11\]        2015   China     Asian       Gastric Cancer               455           660            OS        8     M
  Yang\[12\]       2015   China     Asian       Hepatocellular carcinoma     189           300            OS        9     M
  Hong\[9\]        2015   China     Asian       Small Cell Lung Cancer       919           1600           OS        8     M
  Gardini\[13\]    2016   Italy     Caucasian   Hepatocellular carcinoma     56            360            OS,PFS    9     M
  Wang\[14\]       2016   China     Asian       Hepatocellular carcinoma     163           330            TTR       8     M
  Geng\[8\]        2016   China     Asian       ESCC                         916 and 759   307            OS        8     M
  Loll\[15\]       2016   Italy     Caucasian   Prostate cancer              230           535            OS        9     M
  Loll\[16\]       2016   Italy     Caucasian   Renal cell cancer            335           730            OS, PFS   8     M
  Huang\[17\]      2016   China     Asian       Gastric Cancer               455           572            OS        7     M
  Ha\[18\]         2016   Korea     Asian       Biliary tract cancer         158           572            OS        9     M
  Gao\[10\]        2016   China     Asian       Hepatocellular carcinoma     183           330            OS,TTR    8     U
  Passardi\[19\]   2016   Italy     Caucasian   Colorectal cancer            289           730            OS, PFS   7     M
  Jin\[20\]        2017   China     Asian       MBJ                          33            644            OS        9     M
  Feng\[21\]       2017   China     Asian       ESCC                         298           410            CSS       8     M
  Tong\[22\]       2017   China     Asian       non-small cell lung cancer   332           660            OS        9     M
  wang\[23\]       2017   China     Asian       Gastric Cancer               444           660            OS        9     M
  Yang \[24\]      2017   China     Asian       Colorectal cancer            95            460.66         OS,PFS    9     U
  Yu\[25\]         2017   China     Asian       Acral Melanoma               226           615            OS, RFS   9     M
  Conroy\[26\]     2017   France    Caucasian   Hepatocellular carcinoma     156           600            OS        8     M
  Wang\[27\]       2017   China     Asian       ESCC                         280           560            OS, DFS   7     M
  Chen\[28\]       2017   China     Asian       Colorectal cancer            430           340            OS,PFS    7     M

Abbreviations: ESCC: esophageal squamous cell carcinoma; MBJ: Malignant obstructive jaundice; OS: overall survival; PFS: progress-free survival; TTR: time to recurrent; CSS: cancer-specific survival; RFS: elapse-free survival; DFS: disease-free survival; U: univariate; M: multivariate; NOS: Newcastle-Ottawa Scale.

###### 

Summary of the subgroup analysis between SII and OS

  Subgroup                   No. study   HR     95%CI        *P*       *P* for subgroup difference   Heterogeneity   
  -------------------------- ----------- ------ ------------ --------- ----------------------------- --------------- ---------
  Ethnicity                                                            \<0.001                                       
  Asian                      17          1.26   1.12 -1.40   \<0.001                                 81.4            \<0.001
  Caucasian                  5           1.55   0.84-2.27    0.009                                   64.5            0.024
  Cancer type                                                          \<0.001                                       
  Hepatocellular carcinoma   6           2.11   1.59-2.38    \<0.001                                 0               0.71
  Gastric Cancer             3           1.43   1.12-1.83    0.005                                   53.4            0.117
  ESCC                       3           1.50   1.09-2.06    0.013                                   75.9            0.016
  Urinary system cancer      2           1.82   1.44-2.32    \<0.001                                 0               0.931
  Other                      3           1.77   1.30-2.41    \<0.001                                 53.1            0.119
  Biliary system cancer      2           1.84   0.35-9.63    0.469                                   76.1            0.041
  Colorectal cancer          3           1.57   0.65-3.79    0.313                                   94              \<0.001
  Sample size                                                          \<0.001                                       
  Sample size≤255            11          1.14   0.89-1.39    \<0.001                                 34.4            0.123
  Sample size\>255           11          1.31   1.16-1.45    \<0.001                                 87.8            \<0.001
  Cutoff value                                                         \<0.001                                       
  ≤560                       11          1.21   1.00-1.43    \<0.001                                 83.9            \<0.001
  \>560                      11          1.32   1.14-1.51    \<0.001                                 61.7            0.004

Abbreviations: ESCC: esophageal squamous cell carcinoma; No: number; HR: hazard ratio; CI: confidence interval.
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